|
KMID : 1023620050290020069
|
|
Reproductive and Developmental Biology
2005 Volume.29 No. 2 p.69 ~ p.73
|
|
|
Biological Activity of Recombinant Human Erythropoietin (EPO) In Vivo and In Vitro
|
|
Park Jong-Ju
Kang Hye-Young
Nam In-Suk
Lee Hyen-Gi
Park Hee-Ja
Kim Min-Su
Chung Yun-Hi
Naidansuren Purevjargal
Lee Poong-Yun
Park Jin-Gi
Seong Hwan-Hoo
Chang Won-Kyong
Kang Myung-Hwa
|
|
|
Abstract
|
|
|
|
The hematopoietic growth factor erythropoietin (EPO) is required for the maintenance, proliferation, and differentiation of the stem cells that produce erythrocytes. To analyse the biological activity of the recombinant human EPO (rec-hEPO), we have cloned the EPO cDNA and genomic DNA and produced rec-hEPO in the CHO cell lines. The growth and differentiation of EPO-dependent human leukemic cell line (F36E) were used to measure cytokine dependency and in vitro bioactivity of rec-hEPO. MIT assay values were increased by survival of F36E cells at 24h or 72h. The hematocrit and RBC values were increased by subcutaneous injection of 20 IU (in mice) and 100IU(in rats) rec-hEPO. Hematocrit values remarkably increased at (in mice) and (in rats). The pharmacokinetic behavior with injection of 6 IU of rec-hEPO remained detectable after 24 h in all mice tested. The highest peat appeared at 2h after injection. The long half-life of rec-hEPO is likely to confer clinical advantages by allowing less frequent dosing in patients treated for anemia. These data demonstratethat ree-hEPO produced in this study has a potent activity in vivo and in vitro. The results also suggest that biological activity of ree-hEPO could be remarkably enhanced by genetic engineering that affects the potential activity, including mutants with added oligosaccharide chain and designed to produce EPO-EPO fusion protein.
|
|
|
KEYWORD
|
|
|
Erythropoietin, Recombinant, Biological activity, Pharmacokinetic behavior
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|